GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Cyclically Adjusted PS Ratio

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Cyclically Adjusted PS Ratio : 21.27 (As of Apr. 28, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Arrowhead Pharmaceuticals's current share price is $22.12. Arrowhead Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $1.04. Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 21.27.

The historical rank and industry rank for Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

ARWR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.49   Med: 35.55   Max: 231.97
Current: 21.27

During the past years, Arrowhead Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 231.97. The lowest was 4.49. And the median was 35.55.

ARWR's Cyclically Adjusted PS Ratio is ranked worse than
84.36% of 505 companies
in the Biotechnology industry
Industry Median: 5.24 vs ARWR: 21.27

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.033. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.04 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.86 114.48 124.89 42.44 25.83

Arrowhead Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.41 25.65 35.10 25.83 29.43

Competitive Comparison of Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.12/1.04
=21.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Arrowhead Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.033/129.4194*129.4194
=0.033

Current CPI (Dec. 2023) = 129.4194.

Arrowhead Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.001 99.695 0.001
201406 0.001 100.560 0.001
201409 0.001 100.428 0.001
201412 0.003 99.070 0.004
201503 0.001 99.621 0.001
201506 0.002 100.684 0.003
201509 0.001 100.392 0.001
201512 0.001 99.792 0.001
201603 0.001 100.470 0.001
201606 0.001 101.688 0.001
201609 0.000 101.861 0.000
201612 0.061 101.863 0.078
201703 0.120 102.862 0.151
201706 0.125 103.349 0.157
201709 0.117 104.136 0.145
201712 0.047 104.011 0.058
201803 0.008 105.290 0.010
201806 0.008 106.317 0.010
201809 0.128 106.507 0.156
201812 0.363 105.998 0.443
201903 0.491 107.251 0.592
201906 0.432 108.070 0.517
201909 0.429 108.329 0.513
201912 0.303 108.420 0.362
202003 0.231 108.902 0.275
202006 0.269 108.767 0.320
202009 0.075 109.815 0.088
202012 0.207 109.897 0.244
202103 0.316 111.754 0.366
202106 0.441 114.631 0.498
202109 0.367 115.734 0.410
202112 0.262 117.630 0.288
202203 1.407 121.301 1.501
202206 0.306 125.017 0.317
202209 0.298 125.227 0.308
202212 0.590 125.222 0.610
202303 1.353 127.348 1.375
202306 0.148 128.729 0.149
202309 0.150 129.860 0.149
202312 0.033 129.419 0.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arrowhead Pharmaceuticals  (NAS:ARWR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Arrowhead Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Executives
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105